<DOC>
	<DOCNO>NCT01768195</DOCNO>
	<brief_summary>The purpose study identify effect prophylactic entecavir HBsAg Positive lymphoma patient treat rituximab-based immunochemotherapy .</brief_summary>
	<brief_title>Prophylactic Use Entecavir HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy</brief_title>
	<detailed_description>HBsAg Positive lymphoma patient treat entecavir receive rituximab-based immunochemotherapy . Entecavir 0.5mg daily administrate day 1 immunochemotherapy and/or chemotherapy 12 month complete immunochemotherapy and/or chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>treatmentnaive patient Bcell lymphoma HBsAg positive baseline treat rituximabbased immunochemotherapy life expectancy 3 month young 18 year old HBsAg negative baseline pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>rituximab</keyword>
</DOC>